← All organizations
Highest phase reached
Phase 4
Timeline
1990s
- Jun 1, 1992
Medac— Founded
2010s
- Jul 10, 2014
naltrexone— NDA Secondary Org
Drugs by trial phase (44 distinct, 43 trials)
Phase 4 (4 own, 0 via acquisition)
Phase 3 (15 own, 0 via acquisition)
Indications
Studied for
- Arterial Occlusive Diseases
- Arthritis
- Arthritis, Rheumatoid
- Brain Neoplasms
- Carcinoma
- Carcinosarcoma
- Cholangiocarcinoma
- Colorectal Neoplasms
- Diabetic Foot
- Disease
- Esophageal Neoplasms
- Gallbladder Neoplasms
- Glioblastoma
- Glioma
- Graft vs Host Disease
- Hematologic Diseases
- Hematologic Neoplasms
- Hemoglobinopathies
- Ischemia
- Leiomyosarcoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Juvenile
- Melanoma
- Metabolism, Inborn Errors
- Mixed Tumor, Mullerian
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Pancytopenia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Psoriasis
- Rectal Neoplasms
- Syndrome
- Urinary Bladder Neoplasms
Marketed drugs (1)
Recent trials (43)
- NCT07025824CollaboratorPhase 2Sep 30, 2025
- NCT06781879CollaboratorPhase 4Feb 24, 2025
- NCT06239311Lead sponsorPhase 3Feb 27, 2024
- NCT06075706Lead sponsorPhase 2Oct 31, 2023
- NCT05534620Lead sponsorPhase 1Oct 31, 2022
- NCT04629833Lead sponsorPhase 3Aug 16, 2021
- NCT04469699CollaboratorPhase 2Nov 30, 2020
- NCT04738162CollaboratorPhase 2Sep 25, 2020
- NCT04195633CollaboratorPhase 2Jan 31, 2020
- NCT03156790Lead sponsorPhase 2Dec 15, 2017
- NCT03254589CollaboratorPhase 4Oct 1, 2017
- NCT02349906Lead sponsorPhase 2Apr 1, 2015
- NCT02308553CollaboratorPhase 1/Phase 2Jan 1, 2015
- NCT02333058Lead sponsorPhase 2Jul 1, 2014
- NCT02170090CollaboratorPhase 3Apr 1, 2014
Details
- Founded
- Augusta, GA, US Jun 1, 1992
- Last known activity
- Sep 30, 2025